THE MODERN BIO← All tests

MODERN BIO / TESTING LAB / GENETICS

Standard of care

TEST PASSPORT · REVIEWED JULY 2026

Hereditary cancer + cardiac gene panels

Use medical-grade genetics when personal or family history makes the result actionable.

Targeted panels can identify inherited variants that alter surveillance or family testing. Pre- and post-test counseling matter because uncertain and incidental findings are common.

Genetics diagnostic testing visualization
CLINICAL GENETICS / DECISION GUIDE
ACCESSAt homeSaliva or blood
TURNAROUND2–6 weeksProvider and location dependent
RELATIVE COST$$$–$$$$Total downstream cost matters
COMMERCE STATUSClinician pathwayEligibility screen + genetic counseling + medical-grade panel

HOW TO USE THIS PAGE

Decide whether this test deserves a place in your plan.

  1. 01
    Confirm the question

    Be clear about what decision the result would change before ordering.

  2. 02
    Check fit and preparation

    Review who it helps, who should pause and how to protect the quality of the signal.

  3. 03
    Plan the response

    Know what you will do with a normal, abnormal or unclear result.

01 / WHO SHOULD TAKE IT

Fit the test to
the person.

Testing is useful when the result can change a real decision. These are educational selection criteria, not a diagnosis or personal order.
GOOD-FIT QUESTIONS
  • People meeting clinical criteria based on cancer, cardiac or family history
  • Families with a known pathogenic variant
  • People prepared for medical and family implications
PAUSE BEFORE ORDERING
  • Assuming a negative consumer panel eliminates inherited risk
  • Ordering broad panels without a plan for uncertain variants

02 / SIGNAL VS. STORY

What it tells you.
What it cannot.

THE SIGNAL
01

Pathogenic/likely pathogenic variants in tested genes

02

Whether targeted family testing may be useful

03

Potential changes to surveillance when supported by guidelines

THE LIMIT
01

Not every risk gene or variant is known or tested

02

A variant of uncertain significance is not a positive diagnosis

03

Privacy, insurance and family implications deserve discussion

03 / MARKERS + RANGES

Read the panel
without chasing flags.

The report should show its own method, units and laboratory reference interval. Clinical decision thresholds may be different from a lab interval. We do not invent a universal “optimal” range where authoritative guidance does not support one.
01Panel and methodology

Use the laboratory unit and method, then interpret with symptoms, trend and the decision this marker can change.

02Pathogenicity classification

Use the laboratory unit and method, then interpret with symptoms, trend and the decision this marker can change.

03Deletion/duplication coverage

Use the laboratory unit and method, then interpret with symptoms, trend and the decision this marker can change.

04Confirmatory method

Use the laboratory unit and method, then interpret with symptoms, trend and the decision this marker can change.

05Family variant testing

Use the laboratory unit and method, then interpret with symptoms, trend and the decision this marker can change.

MEN, WOMEN + LIFE-STAGE CONTEXT

The correct range is personal context—not pink versus blue numbers.

Where biology differs, we call it out. Clinical interpretation should also reflect organs present, hormone therapy, pregnancy, age, medications and health history.

Women

Ovary, breast and uterine history may change panel criteria and surveillance; genes can be inherited from either parent.

Men

Male breast, prostate, pancreatic and cardiac history can be highly informative; genes can be passed to all children.

04 / PREPARATION

Protect the quality
of the signal.

The best assay cannot rescue the wrong timing, wrong specimen or wrong question. Follow the ordering clinician and laboratory instructions when they differ from this general guide.
01Pedigree

Collect cancer/cardiac diagnoses and ages from both sides of the family.

02Counseling

Clarify what positive, negative and uncertain results could change.

03Privacy

Read data retention, research use and deletion policies before consenting.

REPEAT CADENCEUsually once, with reinterpretation as variant knowledge changes. Retesting is considered when panel technology or family information changes meaningfully.

05 / AFTER THE RESULT

Turn the number
into a next step.

  1. 01

    Confirm medical action through a genetics professional

  2. 02

    Offer cascade testing to relatives when appropriate

  3. 03

    Keep the original laboratory report for future reinterpretation

DO NOT WAIT ON A CONSUMER TEST

Do not delay evaluation of a suspicious symptom while waiting for genetics

Major distress or family conflict deserves counseling support

06 / MODERN BIO SELECT

Built for a responsible purchase path.

Any future sale must include consent, privacy clarity, counseling and confirmatory care.
CLINICIAN PATHWAY

Hereditary cancer + cardiac gene panels

Future format
Eligibility screen + genetic counseling + medical-grade panel
Price position
Panel-specific transparent price
Before checkout
Eligibility · method · privacy · total cost · interpretation · abnormal-result routing
Join product early access →

07 / SCIENTIFIC FOUNDATION

Open the source.
Check the claim.

We prefer official guidance, clinical standards and primary scientific records. A source supports the specific point described on this passport—not every marketing use of the test.